Bahram Bodaghi

Bahram Bodaghi

Auto-generated profile, based on publicly available information

Bahram Bodaghi

Sorbonne University, APHP, Pitié-Salpêtrière Hospital

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
GHG Hatemi
G Hatemi
ASA Silman
A Silman
DBD Bang
D Bang
BBB Bodaghi
B Bodaghi
ACA M Chamberlain
A M Chamberlain
ECEULAR Expert Committee
EULAR Expert Committee

1 November 2011 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
MSMarc D. De Smet
Marc D. De Smet
STSimon R.J. Taylor
Simon R.J. Taylor
BBBahram Bodaghi
Bahram Bodaghi
EMElisabetta Miserocchi
Elisabetta Miserocchi
PMPhilip I. Murray
Philip I. Murray
SLSue Lightman
Sue Lightman

28 December 2009 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
BNBénédicte Neven
Bénédicte Neven
IMIsabelle Marvillet
Isabelle Marvillet
CTCeline Terrada
Celine Terrada
AFAlice Ferster
Alice Ferster
NBNathalie Boddaert
Nathalie Boddaert
PQPierre Quartier
Pierre Quartier
Objective: Cryopyrin‐associated periodic syndromes (CAPS) are a group of rare autoinflammatory diseases. Neonatal‐onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic, cutaneous, articular syndrome (CINCA syndrome) is the most severe phenotype, with fever, rash, articular manifestations, and neurologic and neurosensory involvement. CAPS are caused by mutations in CIAS1, the gene encoding NLRP3, which plays a critical role in interleukin‐1 (IL‐1) processing. Anakinra, an IL‐1 receptor antagonist, has been shown to be an effective treatment; however, data on long‐term efficacy and safety have been sparse. This study was undertaken to assess the long‐term efficacy and safety of anakinra treatment in patients with NOMID/CINCA syndrome.Methods: We retrospectively analyzed the medical records of NOMID/CINCA syndrome patients referred to 2 centers, who had started anakinra treatment before June 2007.Results: There were 10 patients with NOMID/CINCA syndrome who had been treated with anakinra. The patients' ages at the time anakinra treatment was initiated ranged from 3 months to 20 years. They had been followed up for 26–42 months. Sustained efficacy in the treatment of systemic inflammation and, in some cases, neurologic involvement and growth parameters, was achieved. The dosage of anakinra required for efficacy ranged from 1 to 3 mg/kg/day in the 8 oldest patients and from 6 to 10 mg/kg/day in the 2 youngest. Residual central nervous system inflammation and deafness persisted in some patients, especially if there had been a delay in diagnosis and treatment. Secondary amyloidosis persisted in cases in which it was present at treatment initiation, but no new lesions developed. No effect on overgrowth arthropathy was observed. Adverse events consisted of mild injection‐site reactions.Conclusion: The present results indicate that anakinra treatment is effective over the long term in NOMID/CINCA syndrome. However, treatment has to be initiated before irreversible lesions develop, and, particularly in very young patients, dosage adjustment is required.

1 July 2001 in Medicine
Verified
Journal Article
Closed access
BBBahram Bodaghi
Bahram Bodaghi
NCNathalie Cassoux
Nathalie Cassoux
BWBertrand Wechsler
Bertrand Wechsler
DHDaniele Hannouche
Daniele Hannouche
CFChristine Fardeau
Christine Fardeau
PLPhuc Lehoang
Phuc Lehoang

7 September 1998 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BBBahram Bodaghi
Bahram Bodaghi
TJThomas R. Jones
Thomas R. Jones
DZDonato Zipeto
Donato Zipeto
CVClaudio Vita
Claudio Vita
LSLei Sun
Lei Sun
SMSusan Michelson
Susan Michelson
Human cytomegalovirus (HCMV), a betaherpesvirus, has developed several ways to evade the immune system, notably downregulation of cell surface expression of major histocompatibility complex class I heavy chains. Here we report that HCMV has devised another means to compromise immune surveillance mechanisms. Extracellular accumulation of both constitutively produced monocyte chemoattractant protein (MCP)-1 and tumor necrosis factor–superinduced RANTES (regulated on activation, normal T cell expressed and secreted) was downregulated in HCMV-infected fibroblasts in the absence of transcriptional repression or the expression of polyadenylated RNA for the cellular chemokine receptors CCR-1, CCR-3, and CCR-5. Competitive binding experiments demonstrated that HCMV-infected cells bind RANTES, MCP-1, macrophage inflammatory protein (MIP)-1β, and MCP-3, but not MCP-2, to the same receptor as does MIP-1α, which is not expressed in uninfected cells. HCMV encodes three proteins with homology to CC chemokine receptors: US27, US28, and UL33. Cells infected with HCMV mutants deleted of US28, or both US27 and US28 genes, failed to downregulate extracellular accumulation of either RANTES or MCP-1. In contrast, cells infected with a mutant deleted of US27 continues to bind and downregulate those chemokines. Depletion of chemokines from the culture medium was at least partially due to continuous internalization of extracellular chemokine, since exogenously added, biotinylated RANTES accumulated in HCMV-infected cells. Thus, HCMV can modify the chemokine environment of infected cells through intense sequestering of CC chemokines, mediated principally by expression of the US28-encoded chemokine receptor.

31 March 2007 in Rheumatology
Verified
Journal Article
Open access
PDF file
PSPetros P. Sfikakis
Petros P. Sfikakis
NMN. Markomichelakis
N. Markomichelakis
EAE. Alpsoy
E. Alpsoy
SAS. Assaad-Khalil
S. Assaad-Khalil
BBB. Bodaghi
B. Bodaghi
HYH. Yazici
H. Yazici
Behçet's disease (BD) is a multisystem, chronic-relapsing, inflammatory disorder classified among the vasculitides [ 1 , 2 ]. It has a worldwide distribution being more prevalent in the Middle East, Far East and the Mediterranean basin [ 3 ]. The diagnosis is entirely based on clinical grounds since no pathognomonic laboratory findings exist. International study group classification criteria used for BD patients participating in research protocols depend on the presence of recurrent oral ulceration plus any two of the following: recurrent genital ulcerations, ocular lesions (anterior or posterior uveitis, or cells in the vitreous on slit lamp examination, or retinal vasculitis), typical skin lesions (erythema nodosum, pseudofollicullitis) and a positive pathergy (skin hyperreactivity) test [ 4 , 5 ]. The clinical picture of BD is diverse and while recurrent mucocutaneous lesions are usually the only symptoms at the onset of the disease, most patients develop ocular and/or articular, vascular, central nervous system and gastrointestinal inflammation later on. Vital organ involvement may lead, despite treatment, not only to severe morbidity but also to increased mortality especially among young males [ 1 , 2 , 6 ].